Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy

Treatment with busulphan and/or hydroxyurea rarely produces remission in patients with chronic myelogenous leukaemia (CML) in chronic phase. HLA‐identical sibling transplants almost always produce remission, and only about 20% of patients relapse post‐transplant. The increased anti‐leukaemic efficac...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1997-10, Vol.99 (1), p.23-29
Main Authors: Zhang, Mei‐Jie, Baccarani, Michele, Gale, Robert Peter, McGlave, Philip B., Atkinson, Kerry, Champlin, Richard E., Dicke, Karel A., Giralt, Sergio, Gluckman, Eliane, Goldman, John M., Klein, John P., Herzig, Roger H., Masaoka, Tohru, O'Reilly, Richard J., Rozman, Ciril, Rowlings, Philip A., Sobocinski, Kathleen A., Speck, Bruno, Zwaan, Ferry E., Horowitz, Mary M.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
bone marrow transplant
Bone Marrow Transplantation
Bone marrow, stem cells transplantation. Graft versus host reaction
busulphan
chemotherapy
CML
Cohort Studies
Combined Modality Therapy
Female
Humans
hydroxyurea
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
Male
Medical sciences
Middle Aged
Recurrence
Risk Factors
Survival Analysis
Survival Rate
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Transplantation Conditioning
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment with busulphan and/or hydroxyurea rarely produces remission in patients with chronic myelogenous leukaemia (CML) in chronic phase. HLA‐identical sibling transplants almost always produce remission, and only about 20% of patients relapse post‐transplant. The increased anti‐leukaemic efficacy of transplants results from intensive pretransplant treatment and immune‐mediated anti‐leukaemia effects. We studied 433 patients surviving  2 years after diagnosis of CML to determine if patients who have relapsed after a transplant in chronic phase have longer survival from diagnosis than comparable subjects receiving chemotherapy. The chemotherapy cohort included 344 adults
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1997.3313150.x